Sugi Predict

Sugi Predict / Compounds / SCHEMBL751264

SCHEMBL751264

SCHEMBL751264

C=C(OCC)c1ccnc(SC)n1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.38
▸ TDP1 Q9NUW8 3/20 0.38
▸ POLB P06746 2/20 0.38
▸ KMT2A Q03164 4/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ SYK P43405 2/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ MAPT P10636 4/20 0.35
▸ HPGD P15428 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ HTT P42858 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6989832 0.81 CYP1A2 (0.56) ALDH1A1TDP1POLBKMT2AMEN1
SCHEMBL30625833 0.80 CYP1A2 (0.37) ALDH1A1MAPTHPGDIRAK4LMNA
SCHEMBL15573479 0.78 DGAT1 (0.38) ALDH1A1TDP1MAPTHPGDSMN1; SMN2
SCHEMBL26113629 0.77 NCOA1 (0.44) ALDH1A1TDP1POLBKMT2AMEN1
SCHEMBL31374459 0.77 NCOA1 (0.44) ALDH1A1TDP1POLBKMT2AMEN1
SCHEMBL13060099 0.76 KMT2A (0.39) ALDH1A1TDP1POLBKMT2AMEN1
SCHEMBL17820401 0.76 IRAK4 (0.35) ALDH1A1POLBMAPTHPGDSMN1; SMN2
SCHEMBL11536235 0.76 ALDH1A1 (0.39) ALDH1A1TDP1POLBKMT2AMEN1
SCHEMBL13279457 0.75 ALDH1A1 (0.40) ALDH1A1TDP1POLBKMT2AMEN1
SCHEMBL23528186 0.74 ALDH1A1 (0.36) ALDH1A1POLBMAPTHPGDIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885346-A1 AMINOPYRIMIDINE COMPOUND USED FOR INHIBITING ACTIVITY OF PROTEIN KINASE Shenzhen TargetRx, Inc. (CN) 2021-09-29 — — EP disclosed
WO-2020125391-A1 AMINOPYRIMIDINE COMPOUND USED FOR INHIBITING ACTIVITY OF PROTEIN KINASE 深圳市塔吉瑞生物医药有限公司 2020-06-25 — — WO disclosed
EP-1439174-B1 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-21 — — EP disclosed
EP-1439174-B1 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-21 — — EP disclosed
EP-1628968-B1 4-IMIDAZOLIN-2-ONE COMPOUNDS MITSUBISHI TANABE PHARMA CORP (JP) 2011-04-06 — — EP disclosed
US-7846933-B2 such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-12-07 — — US disclosed
US-7846933-B2 such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-12-07 — — US disclosed
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS KUBO AKIRA 2009-04-02 — — US disclosed
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS KUBO AKIRA 2009-04-02 — — US disclosed
US-7473695-B2 4-imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-06 — — US disclosed
US-7473695-B2 4-imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-06 — — US disclosed
US-7473695-B2 4-imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-06 — — US disclosed
EP-1628968-A4 4-IMIDAZOLIN-2-ONE COMPOUNDS MITSUBISHI TANABE PHARMA CORP (JP) 2008-03-05 — — EP disclosed
US-20080015353-A1 PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF AJINOMOTO CO., INC. (JP) 2008-01-17 — — US disclosed
US-20080015353-A1 PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF AJINOMOTO CO., INC. (JP) 2008-01-17 — — US disclosed
EP-1849761-A1 PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF Ajinomoto Co., Inc. (JP) 2007-10-31 — — EP disclosed
EP-1628968-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2006-03-01 — — EP disclosed
WO-2004094404-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2004-11-04 — — WO disclosed
US-20040204426-A1 4-Imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-10-14 — — US disclosed
EP-1439174-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2004-07-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015353-A1 PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF DPYD, UMPS, PNPO ALDH1A1 352/4885TDP1 1792/4885POLB 60/4885
US-20040204426-A1 4-Imidazolin-2-one compounds NR3C1, NR3C2, SCN1B ALDH1A1 755/4885TDP1 3398/4885POLB 3833/4885
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS OR10J3, NR4A3, NR3C2 ALDH1A1 1391/4885TDP1 3986/4885POLB 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.